Consideration of both biological and cultural evolution justifies the design of improved pharmacological treatments for obesity and Type 2 diabetes (T2D) that focus on peripheral CB1R antagonism. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.